<div id="readability-page-1"><p>Harrow, Inc. (NASDAQ:HROW - Get Free Report) has been given a consensus rating of &#34;Moderate Buy&#34; by the ten brokerages that are currently  covering the stock, Marketbeat Ratings reports. One analyst  has rated the stock with a sell recommendation, one  has given a hold recommendation and eight have issued  a buy recommendation on  the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $71.4286.</p><p>Several equities analysts have recently issued reports on HROW shares. Zacks Research lowered Harrow from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, September 12th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Harrow in a research report on Wednesday, October 8th. Craig Hallum boosted their target price on Harrow from $54.00 to $64.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 23rd. BTIG Research  restated a &#34;buy&#34; rating and issued a $63.00 price target on shares of Harrow in a research note on Wednesday, September 24th. Finally, LADENBURG THALM/SH SH lifted their price target on shares of Harrow from $64.00 to $66.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 12th.</p><p><b>Read Our Latest Stock Analysis on Harrow</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its holdings in  Harrow by 4.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company's stock worth $259,000 after purchasing an additional 332 shares in the last quarter.  The Manufacturers Life Insurance Company grew its holdings in shares of  Harrow by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after purchasing an additional 341 shares during the last quarter.  Alliancebernstein L.P. increased its stake in shares of  Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company's stock valued at $1,422,000 after buying an additional 500 shares during the period.  Pale Fire Capital SE raised its holdings in  Harrow by 6.8% in the 2nd quarter. Pale Fire Capital SE now owns 8,683 shares of the company's stock valued at $265,000 after buying an additional 550 shares during the last quarter.  Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in  Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock worth $483,000 after buying an additional 790 shares during the period. 72.76% of the stock is currently owned by institutional investors. </p><h2>Harrow Price Performance</h2><p>Shares of NASDAQ:HROW opened at $50.09 on Monday. The firm has a 50 day moving average of $41.78 and a 200-day moving average of $38.83. Harrow has a 12 month low of $20.85 and a 12 month high of $51.30. The company has a current ratio of 2.72, a quick ratio of 2.52 and a debt-to-equity ratio of 5.21. The stock has a market capitalization of $1.86 billion, a PE ratio of -500.85 and a beta of 0.07. </p><p>Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The business had revenue of $71.64 million for the quarter, compared to analysts' expectations of $73.70 million.  On average, equities research analysts predict that  Harrow will post -0.53 EPS for the current fiscal year. </p><h2>About Harrow</h2> (Get Free Report)<p>Harrow Health, Inc <span>NASDAQ: HROW<span></span></span> is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.  </p><p>Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Harrow</li><li>Do not delete, read immediately</li><li>How the Rich Retire</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>How Long Will $1M Last in Retirement?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFJPVw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Harrow Right Now?</h2><p>Before you consider Harrow, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.</p><p>While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HROW

<p>Harrow, Inc. (NASDAQ:HROW) has received a consensus rating of "Moderate Buy" from ten brokerages. One analyst rated it as a sell, one as hold, and eight as buy. The average 12-month target price is $71.43. Recent reports include Zacks lowering its rating to hold, while Craig Hallum and BTIG Research issued buy ratings with target prices of $64.00 and $63.00, respectively. Harrow's stock opened at $50.09, with a market cap of $1.86 billion and a recent EPS of $0.33, exceeding estimates. The company specializes in ophthalmic therapeutics and diagnostics.</p>

Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of "Moderate Buy" from Analysts